The Multiple System Atrophy Coalition has compiled a list of over thirty potential treatments currently in development for MSA. The graphic below will enable you to see at a glance how far along they are in the drug development process. To assist you in finding more detailed information we’ve divided the list into Clinical Trials and Laboratory Studies. Explore the links below to learn more.
Remember to check back regularly to find out what’s new in the Multiple System Atrophy Treatment Pipeline and be sure to Sign Up Here for our newsletter mailing list to stay informed of the latest updates.
September 29, 2021: Lupin Launches Droxidopa Capsules in the United States
September 22, 2021: ICBII Announces Approval of Its 7th Patent on Blood-Brain Barrier Permeable Technology, Moving Closer to Clinical Trials on its drugs for Alzheimer’s, Parkinson’s, and Other Neuro-Degenerative Diseases
July 15, 2021: New Publication Demonstrates ATH434 is Neuroprotective
June 11, 2021: Updated Q&A on Verdiperstat
February 5, 2021: Biohaven Shares Verdiperstat’s Mechanism of Action
August 4, 2020: New data independently confirms and extends laboratory findings and expands safety profile of ATH434 (PBT-434)
July 1, 2020: Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 (PBT-434)
April 30, 2020: MSA Coalition Blog – Caution When it Comes to Stem Cells for MSA
April 16, 2020: MSA Coalition Blog – Q & A about Verdiperstat Clinical Trial
January 21, 2020: Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
January 14, 2020: European Commission approves Orphan Designation for Alterity’s lead drug candidate (PBT-434)
December 18, 2019: MODAG Initiates First-in-Human Phase 1 Clinical Trial for Anle138b
November 18, 2019: FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. (Fingolimod)
November 4, 2019: Researchers begin trial of drug to slow progression of neurodegenerative condition Multiple System Atrophy (Exendin-4)
October 5, 2019: A vaccine for Parkinson’s disease shows promising results (PD01A)
August 2, 2019: Green Tea Extract Shows No Significant Benefit for Multiple System Atrophy (ECGC)
CLINICAL TRIALS & STUDIES
EXPERIMENTAL LAB WORK
Are you interested in participating in a clinical trial? Visit www.clinicaltrials.gov, enter the name of the disease and you’ll be able to stay abreast of the latest clinical trial news. You can also enroll in the Fox Trial Finder which not only allows you to share your information for future research studies but will also inform you of any research study or clinical trial for which you qualify.
More MSA Research Highlights
In this video, recorded at the MSA Coalition’s annual conference in September 2019, Dr. Gregor Wenning, Chairman of the MSA Coalition’s Scientific Advisory Board discusses MSA Coalition funded research and promising treatments to watch.
A Track Record of Success
Explore reports and articles from MSA Coalition supported research.
Building Hope Through Research
Since 2013, the Multiple System Atrophy Coalition has funded 49 MSA focused research projects for a total of $2.5 Million.
Explore the links below to learn more about our research goals and the outcomes of our funded projects.
Click on each category to read about these exciting research projects.
- Pathogenesis: Uncovering the cause of MSA
- Diagnostic Biomarkers: Improving methods for better diagnosis
- Preclinical: Evaluating potential new treatments in the lab
- Clinical: Facilitating clinical studies of potential new treatments in MSA patients
We are making an impact!
© Copyright The Multiple System Atrophy Coalition 1989-2021. All Rights Reserved.